Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China

被引:47
作者
Dye, C [1 ]
Zhao, FZ
Scheele, S
Williams, B
机构
[1] WHO, Communicable Dis Control Prevent & Eradicat, CH-1211 Geneva 27, Switzerland
[2] Minist Hlth, Dept Dis Control, Natl TB Control Ctr, Beijing 100025, Peoples R China
[3] CSIR, Johannesburg, South Africa
关键词
disease burden; epidemiology; mathematical modelling; standard short-course chemotherapy; TB;
D O I
10.1093/ije/29.3.558
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Tuberculosis (TB) is still amongst the most important causes of human morbidity and mortality killing approximately two million people each year. Standard short-course chemotherapy (SSCC) can rapidly control illness and dramatically reduce the chance of death, but the impact of treatment has rarely been evaluated in these terms. Method We developed a mathematical model that makes use of routinely-collected data to calculate the number of deaths directly prevented by TB treatment (i.e. excluding those due to reduced transmission). The method was applied to the world's largest TB control programme covering over 500 million people in 12 provinces of China. Results Counties which had been enrolled in the programme since 1991 were, by 1997, preventing at least 46% (37-56%) of the TB deaths that would otherwise have occurred. If replicated across the entire TB control programme area, this would amount to 30 000 (range 26 000-59 000) deaths directly prevented each year. Conclusions Short-course chemotherapy has substantially reduced TB mortality in half of China. The analytical method described here could be applied to TB control operations in many other countries, and should help to quantify the true burden of tuberculosis alleviated by SSCC.
引用
收藏
页码:558 / 564
页数:7
相关论文
共 12 条
[1]  
[Anonymous], 1979, The Advanced Theory of Statistics
[2]  
[Anonymous], 1864 WORLD BANK POL
[3]   Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].
Dye, C ;
Scheele, S ;
Dolin, P ;
Pathania, V ;
Raviglione, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686
[4]   Prospects for worldwide tuberculosis control under the WHO DOTS strategy [J].
Dye, C ;
Garnett, GP ;
Sleeman, A ;
Williams, BG .
LANCET, 1998, 352 (9144) :1886-1891
[5]  
Murray C. J. L., 1996, GLOBAL BURDEN DIS, VII
[6]   COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN 3 SUB-SAHARAN AFRICAN COUNTRIES [J].
MURRAY, CJL ;
DEJONGHE, E ;
CHUM, HJ ;
NYANGULU, DS ;
SALOMAO, A ;
STYBLO, K .
LANCET, 1991, 338 (8778) :1305-1308
[7]  
MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1
[8]  
Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127
[9]   The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection [J].
Vynnycky, E ;
Fine, PEM .
EPIDEMIOLOGY AND INFECTION, 1997, 119 (02) :183-201
[10]  
*WHO, 1999, PUBL WHO